Navigating Aspirin Hypersensitivity in Patients Undergoing Percutaneous Coronary Intervention

Area of Science:

• Cardiology
• Clinical Immunology
• Pharmacology

Background:

• Aspirin hypersensitivity is a significant clinical issue for patients with coronary artery disease (CAD), especially those requiring percutaneous coronary intervention (PCI).
• Severe reactions like angioedema or anaphylaxis underscore the need for diagnostic challenge tests and tolerance induction strategies.
• Currently, managing aspirin hypersensitivity often requires a highly individualized approach due to the lack of validated alternative antiplatelet regimens.

Observation:

• A 61-year-old female with end-stage renal disease (ESRD) presented with heart failure and elevated troponins during a hypertensive emergency.
• Left heart catheterization revealed severe multivessel disease, but PCI was delayed due to suspected aspirin-induced angioedema.
• The patient had no established optimal management strategy for her condition.

Findings:

• Aspirin desensitization was successfully performed.
• Following desensitization, a drug-eluting stent was successfully placed, addressing the severe multivessel disease.
• This case demonstrates the feasibility of aspirin desensitization in managing hypersensitivity.

Implications:

• Highlights the critical need for validated protocols to manage aspirin hypersensitivity in cardiovascular patients.
• Suggests that aspirin desensitization can be a viable strategy when alternative antiplatelet options are limited.
• Emphasizes the importance of personalized treatment approaches in complex clinical scenarios involving drug hypersensitivity.